Staphylococcus Aureus Bacteremia Clinical Trial
Official title:
A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
Patients were randomized 1:1 to ceftobiprole or the comparator regimen. Randomization was stratified by study site, dialysis status, and prior antibacterial treatment use within 7 days before randomization. The three phases of the study were: 1. Screening assessments of up to 72 hours prior to randomization 2. Randomization and subsequent active treatment with intravenous (i.v.) study drug (ceftobiprole or daptomycin ± aztreonam). 3. Post-treatment, comprising an end of trial (EOT) visit (within 72 hours of last study-drug administration), Day 35 (± 3 days), Day 42 (± 3 days), and a post-treatment evaluation (PTE) visit on Day 70 (± 5 days) post-randomization. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05862025 -
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
|
N/A | |
| Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
| Recruiting |
NCT00622882 -
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
|
N/A | |
| Recruiting |
NCT06168474 -
Evaluating Simplified Layered Consent for Clinical Trials
|
N/A | |
| Completed |
NCT03163446 -
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
|
Phase 2 | |
| Not yet recruiting |
NCT06336824 -
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
|
Phase 3 | |
| Completed |
NCT02357966 -
A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus
|
Phase 1/Phase 2 | |
| Terminated |
NCT03089697 -
Phase IIa Clinical Study of N-Rephasin® SAL200
|
Phase 2 | |
| Recruiting |
NCT03514446 -
Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia
|
Phase 4 | |
| Not yet recruiting |
NCT04886284 -
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
|
Phase 2 | |
| Withdrawn |
NCT03761953 -
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
|
Phase 4 | |
| Recruiting |
NCT06249451 -
Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
|
N/A | |
| Recruiting |
NCT02098850 -
Staphylococcus Aureus Bacteraemia in Adults
|
N/A | |
| Completed |
NCT01701219 -
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
|
Phase 4 | |
| Recruiting |
NCT05137119 -
Staphylococcus Aureus Network Adaptive Platform Trial
|
Phase 4 | |
| Completed |
NCT03908086 -
Bloodstream Infections in Patients With Rheumatoid Arthritis
|
||
| Terminated |
NCT04160468 -
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
|
Phase 3 | |
| Completed |
NCT02476487 -
The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia
|
N/A | |
| Recruiting |
NCT05184764 -
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
|
Phase 1/Phase 2 | |
| Completed |
NCT01971762 -
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
|
N/A |